Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.21.1
Segments
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
SEGMENTS SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical and genomics laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
  For the three months ended March 31,
(In thousands) 2021 2020
Revenue from services:
Pharmaceutical $ —  $ — 
Diagnostics 506,951  170,839 
Corporate —  — 
$ 506,951  $ 170,839 
Revenue from products:
Pharmaceutical $ 33,945  $ 31,074 
Diagnostics —  — 
Corporate —  — 
$ 33,945  $ 31,074 
Revenue from transfer of intellectual property and other:
Pharmaceutical $ 4,269  $ 9,553 
Diagnostics —  — 
Corporate —  — 
$ 4,269  $ 9,553 
Operating income (loss):
Pharmaceutical $ (19,157) $ (14,126)
Diagnostics 67,014  (18,133)
Corporate (9,420) (8,503)
$ 38,437  $ (40,762)
Depreciation and amortization:
Pharmaceutical $ 7,413  $ 7,121 
Diagnostics 12,576  14,871 
Corporate —  60 
$ 19,989  $ 22,052 
Loss from investment in investees:
Pharmaceutical $ (43) $ (134)
Diagnostics —  — 
Corporate —  — 
$ (43) $ (134)
Revenues:
United States $ 512,871  $ 180,872 
Ireland 7,129  11,901 
Chile 14,152  10,850 
Spain 5,919  4,156 
Israel 2,512  1,707 
Mexico 2,418  1,841 
Other 164  139 
$ 545,165  $ 211,466 
(In thousands) March 31,
2021
December 31,
2020
Assets:
Pharmaceutical $ 1,151,771  $ 1,176,245 
Diagnostics 1,330,183  1,268,738 
Corporate 37,621  28,080 
$ 2,519,575  $ 2,473,063 
Goodwill:
Pharmaceutical $ 241,353  $ 245,793 
Diagnostics 434,809  434,809 
Corporate —  — 
$ 676,162  $ 680,602 
No customer represented more than 10% of our total consolidated revenue during the three months ended March 31, 2021 and 2020. As of March 31, 2021 and December 31, 2020, no customer represented more than 10% of our accounts receivable balance.